Skip to content

Three-dimensional Digital Breast Tomosynthesis Versus Digital Mammography

Three-dimensional Digital Breast Tomosynthesis Versus Digital Mammography: Which Get the Supremacy in Diagnosis of Benign Breast Lesions in Asymptomatic Females

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07145892
Enrollment
255
Registered
2025-08-28
Start date
2024-06-01
Completion date
2025-05-29
Last updated
2025-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asymptomatic Females, Benign Breast Lesions, Diagnosis, Digital Mammography, Digital Tomosynthesis, Three Dimension

Brief summary

This study aimed to compare the supremacy of (3D) tomosynthesis versus (2D) digital mammography in the diagnosis of benign breast lesions in asymptomatic females.

Detailed description

Most of the breast lesions are benign, but much concern is given to malignant lesions because breast cancer is the most common malignancy in women. Mammography is the only study for screening in asymptomatic patients, and it is the initial imaging study in the diagnosis of symptomatic patients, with a sensitivity for suspicious lesions of 86% and a specificity of 57%. In recent years, a significant effort has been expended to develop new approaches to breast imaging, one of which is the use of digital breast tomosynthesis (DBT), which is a pseudo three-dimensional digital mammography system that produces a series of thin-section reconstructed images from low-dose X-ray projections at multiple angles.

Interventions

DEVICEThree-dimensional Digital Breast Tomosynthesis

Patients underwent three-dimensional digital breast tomosynthesis.

DEVICETwo-dimensional Digital Mammography

Patients underwent two-dimensional digital mammography

Sponsors

The General Authority for Teaching Hospitals and Institutes
Lead SponsorNETWORK

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- Women with benign breast lesions.

Exclusion criteria

* Pregnant and lactating female. * Patients who refuse to fill the consent form.

Design outcomes

Primary

MeasureTime frameDescription
Correlation between imaging findings and the final diagnosis6 months post-procedureCorrelation between imaging findings and the final diagnosis was calculated.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026